ERAP1,2 in Recalcitrant Warts

Benha University

Status: Completed

Conditions: Warts

Treatments: Diagnostic Test: endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA; Diagnostic Test: endoplasmic reticulum Aminopeptidase 1 and 2

Study type: Observational

Funder types: Other

Identifiers

NCT06833164

Serum ERAP1 and 2 in warts

Details and patient eligibility

About

The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies. Amino-peptidases (ERAP1, ERAP2) of endoplasmic reticulum are essential for production of antigenic epitopes that attach to the Major Histocompatibility Complex (MHC) class I and activate T-lymphocytes or natural killer (NK) cells. Aim: To assess ERAP1 and ERAP2 serum concentrations in patients with resistant warts.

Enrollment: 200 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients who had a history of incomplete clearance or recurrence following two or more electrocautery sessions and four or more cryocautery treatments and intralesional bleomycin.

Exclusion criteria

• Patients with genital warts
• Patients on systemic steroids or other immunosuppressive treatments
• Immunocompromised individuals
• Patients suffering from chronic systemic diseases
• Pregnant women